Stage III Follow-Up

After treatment, all patients with Stage III melanoma should receive a physical examination, including a skin examination, using the following schedule. Regular chest x-rays, CT scans of the trunk and pelvis, and brain MRI may also be recommended.

Type of Follow-upDescription

Skin Examination

Annually by healthcare provider
Monthly self-examination

Physical Examination

Years 1-2: every 3-6 months
Years 3-5: every 3-12 months
After Year 5: annually as needed
Monthly self-examination of lymph nodes

Imaging Tests

Possibly every 3-12 months to check for recurrence

Brain MRI

Possibly each year

All patients with Stage III melanoma should have a skin examination once a year for life. Patients should have a physical examination every 3-6 months for years 1-2, every 3-12 months for years 3-5, and then once a year as needed.

Imaging tests are recommended if specific signs of cancer appear. You may also receive imaging tests every 3-12 months to check for cancer recurrence that isn’t causing symptoms. Possible tests for screening include a chest x-ray, CT scan, PET/CT scan, and brain MRI. These tests may be done for up to 5 years after treatment has ended. Imaging tests are not recommended after 5 years if there has been no recurrence and no symptoms.

Survival Rates

With treatment, Stage III melanoma is considered intermediate- to high-risk for local recurrence or distant metastasis.

Therefore, early detection of melanoma through skin self-examination and medical examination continues to be of utmost importance.

Large-scale studies have shown the following probabilities of melanoma free survival. Keep in mind that the statistics shown for survival are averages; everyone’s cancer and survival rate is based on many factors and determined on an individual basis.

5 years after treatment 110 years after treatment1

Stage IIIA: 93%

Stage IIIA: 88%

Stage IIIB: 83%

Stage IIIB: 77%

Stage IIIC: 69%

Stage IIIC: 60%

Stage IIID: 32%

Stage IIID: 24%

Living With Melanoma: Free Symposiums

Join leading melanoma experts in an educational symposium for patients and the people who support them.

Sign up Today


1. Gershenwald JE, Final Version of 2017 AJCC Melanoma Staging and Classification.

Please keep me informed.

Receive comprehensive, breaking news about melanoma, research, legislation, and events.

  • This field is for validation purposes and should be left unchanged.